Trial · NCT07912528
Spatial Emanator Deployment Strategies for Malaria Control in Papua New Guinea
NCT07912528, Not applicable, Not yet recruiting, Macfarlane Burnet Institute for Medical Research and Public Health Ltd
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Spatial Emanator Deployment Strategies for Malaria Control in Papua New Guinea. Trials, record NCT07912528. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912528
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Spatial Emanator Deployment Strategies for Malaria Control in Papua New Guinea
- NCT number
- NCT07912528
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 4,350 participants, estimated
- Lead sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
- Conditions
- Malaria
- Interventions
- Spatial emanator outdoor, Spatial emanator indoor
- First posted
- 2026-11-03
- Last updated
- 2026-11-10
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effectiveness of Guardian Spatial Emanator | 12 months | Time to first Plasmodium spp. infection detected by PCR at monthly follow-up visits or symptomatic ad-hoc visit between follow-ups over the 12-month intervention period in cohort participants from the core of the clusters. |
| Secondary | Effectiveness of Guardian Spatial Emanator | 12 months | Time to first PCR-confirmed P. falciparum infection over the 12 months of follow-up. Time to first PCR-confirmed P. vivax infection over the 12 months of follow-up. |
| Secondary | Effectiveness of Guardian Spatial Emanator | 6 months | Time to first PCR-confirmed Plasmodium spp infection over the first 6 months of follow-up. Time to first PCR-confirmed P. falciparum infection over the first 6 months of follow-up. Time to first PCR-confirmed P. vivax infection over the first 6 months of follow-up. |
| Secondary | Effectiveness of Guardian Spatial Emanator | 12 months | Incidence of PCR-confirmed Plasmodium spp infections (first-time \& recurrent together) in first 6m \& full 12m. Incidence of PCR-confirmed Pf infections (first-time \& recurrent together) in first 6m \& full 12m. Incidence of PCR-confirmed Pv infections (first-time \& recurrent together) in first 6m \& full 12m Incidence of clinical episodes of malaria (first-time \& recurrent together) in first 6m \& full 12m Incidence of Pf clinical episodes of malaria (first-time \& recurrent together) in first 6m \& full 12m Incidence of Pv clinical episodes of malaria (first-time \& recurrent together) in first 6m \& full 12m Incidence of new Pf blood stage infections (molecular force of blood-stage infection - Pf molFOB) in first 6m \& full 12m Incidence of new Pv blood stage infections (molecular force of blood-stage infection - Pv molFOB) in first 6m \& full 12m Incidence of new blood stage infections (molecular force of blood-stage infection for Pf and Pv molFOB combined) in first 6m \& full 12m |
| Secondary | Difference between indoor and outdoor arms | 12 months | Time to first Plasmodium spp. infection detected by PCR at monthly follow-up or symptomatic ad-hoc visit between follow-ups visits over the 12-month intervention period in cohort participants from the core of the clusters. |
| Secondary | Sensitivity of the estimates for epidemiological outcomes | 12 months | Spillover-adjusted estimates of intervention effectiveness for epidemiological endpoints, incorporating data from cluster buffer zone participants. |
| Secondary | Anopheles species composition | 12 months | Anopheles species composition in a subset of clusters, in the pre-deployment baseline period and at the end of the intervention. |
| Secondary | Presence of insecticide resistance mutations | 12 months | Prevalence of insecticide resistance markers in a subset of clusters in the pre-deployment baseline period and at the end of the intervention. |
| Secondary | Acceptability of spatial emanators | 12 months | Qualitative outcomes from Photovoice methodology, and associated focus group discussions with community members, followed by thematic analysis of drivers of behaviour change, barriers and enablers of spatial emanator acceptance and consistent use. |
| Secondary | Feasibility of spatial emanators | 12 months | Qualitative outcomes from key informant interviews with key study staff and health system stakeholders at district, provincial, and national level followed by descriptive summary of barriers and enablers to distribution, implementation \& scale-up. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912528
GET https://conductscience.org/api/trials/v1/NCT07912528/registered